Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTEM
āļāļ·āđāļāļāļĢāļīāļĐāļąāļTempus AI Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 30, 2025
āļāļĩāļāļĩāđāļLefkofsky (Eric P)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ2400
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 30
āļāļĩāđāļāļĒāļđāđ600 West Chicago Avenue
āđāļĄāļ·āļāļCHICAGO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ60654
āđāļāļĢāļĻāļąāļāļāđ18335144187
āđāļ§āđāļāđāļāļāđhttps://investors.tempus.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTEM
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 30, 2025
āļāļĩāļāļĩāđāļLefkofsky (Eric P)
Mr. Ryan Fukushima
Chief Operating Officer
Mr. Peter J. Barris
Independent Director
Mr. Eric D. Belcher
Independent Director
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
Mr. James (Jim) Rogers
Chief Financial Officer
Mr. David R. Epstein
Independent Director
Dr. Scott Gottlieb, M.D.
Independent Director
Mr. Eric P. Lefkofsky, J.D.
Mr. Eric P. Lefkofsky, J.D.
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
Mr. Erik J. Phelps, J.D.
Executive Vice President, Chief Administrative and Legal Officer, Assistant Secretary
Executive Vice President, Chief Administrative and Legal Officer, Assistant Secretary
Dr. Jennifer A. Doudna, Ph.D.
Dr. Jennifer A. Doudna, Ph.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Ryan Fukushima
Chief Operating Officer
Mr. Peter J. Barris
Independent Director
Mr. Eric D. Belcher
Independent Director
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
Mr. James (Jim) Rogers
Chief Financial Officer
Mr. David R. Epstein
Independent Director
ARK Genomic Revolution ETF
Franklin Genomic Advancements ETF
KraneShares Artificial Intelligence and Tcnlgy ETF
ROBO Global Artificial Intelligence ETF
First Trust Health Care Alphadex Fund
Innovator IBD 50 Fund ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ARK Genomic Revolution ETF
āļŠāļąāļāļŠāđāļ§āļ12.02%
ARK Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ5.1%
Global X HealthTech ETF
āļŠāļąāļāļŠāđāļ§āļ4.22%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ3.92%
Renaissance IPO ETF
āļŠāļąāļāļŠāđāļ§āļ3.83%
KraneShares Artificial Intelligence and Tcnlgy ETF
āļŠāļąāļāļŠāđāļ§āļ3.05%
AXS Green Alpha ETF
āļŠāļąāļāļŠāđāļ§āļ2.92%
ROBO Global Artificial Intelligence ETF
āļŠāļąāļāļŠāđāļ§āļ2.49%
First Trust Health Care Alphadex Fund
āļŠāļąāļāļŠāđāļ§āļ2.42%
Innovator IBD 50 Fund ETF
āļŠāļąāļāļŠāđāļ§āļ2.22%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ